Immunovant, Inc. Share Price Nasdaq
Equities
US45258J2015
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 14.41M 1.2B | Capitalization | 4.19B 350B |
---|---|---|---|---|---|
Net income 2024 * | -250M -20.84B | Net income 2025 * | -276M -23.01B | EV / Sales 2024 * | - |
Net cash position 2024 * | 653M 54.4B | Net cash position 2025 * | 532M 44.3B | EV / Sales 2025 * | 254 x |
P/E ratio 2024 * |
-16.2
x | P/E ratio 2025 * |
-15.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.87% |
Latest transcript on Immunovant, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01/19/01 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04/21/04 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18/19/18 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18/19/18 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18/19/18 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |